Home Newsfeeds Stifel Initiates Coverage On Greif with Buy Rating, Announces Price Target of $90

Stifel Initiates Coverage On Greif with Buy Rating, Announces Price Target of $90

Stifel analyst Michael Hoffman initiates coverage on Greif (NYSE:GEF) with a Buy rating and announces Price Target of $90.

byBenzinga Newsdesk

September 2, 2022

1 minute read

Stifel analyst Michael Hoffman initiates coverage on Greif (NYSE:GEF) with a Buy rating and announces Price Target of $90.

Oppenheimer Maintains Outperform on Akoustis Technologies, Lowers Price Target to $7

By Benzinga Newsdesk

November 15, 7:33 AM

Oppenheimer analyst Rick Schafer maintains Akoustis Technologies (NASDAQ:AKTS) with a Outperform and lowers the price target from $8 to $7.

AKTS

Lucid Group Signs Battery Supply Agreement With Panasonic Energy

By Shivani Kumaresan

December 13, 12:13 PM

Lucid Group Inc (NASDAQ:LCID) and Panasonic (OTC:PCRFY) Group company Panasonic Energy signed multi-year agreements to supply batteries for the luxury electric…

LCID

Morgan Stanley Maintains Underweight on TTEC Holdings, Lowers Price Target to $50

By Benzinga Newsdesk

August 11, 9:55 AM

Morgan Stanley analyst James Faucette maintains TTEC Holdings (NASDAQ:TTEC) with a Underweight and lowers the price target from $60 to $50.

TTEC

Legal
News

Enveric Biosciences Subsidiary Jay Pharma Receives Decision To Grant European Patent Titled ‘COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER’

By Benzinga Newsdesk

January 10, 3:08 PM

https://register.epo.org/application?number=EP16801851

ENVB

Stifel Initiates Coverage On Greif with Buy Rating, Announces Price Target of $90

Related Posts

Oppenheimer Maintains Outperform on Akoustis Technologies, Lowers Price Target to $7

Lucid Group Signs Battery Supply Agreement With Panasonic Energy

Morgan Stanley Maintains Underweight on TTEC Holdings, Lowers Price Target to $50

Enveric Biosciences Subsidiary Jay Pharma Receives Decision To Grant European Patent Titled ‘COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER’